Search Result

Isoforms Recommended:	p70S6K

Results for "

p70S6K

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (13) AMPK (2) Apoptosis (5) Autophagy (4) EGFR (3) Endogenous Metabolite (1) ERK (1) FAK (1) Glucosidase (1) Glucosylceramide Synthase (GCS) (1) HIF/HIF Prolyl-Hydroxylase (1) HSP (1) HSV (1) Mitochondrial Metabolism (1) mTOR (3) Necroptosis (1) NF-κB (3) Oxidative Phosphorylation (1) p38 MAPK (2) PDK-1 (1) PI3K (3) PKA (3) Proteasome (1) Reactive Oxygen Species (1) Ribosomal S6 Kinase (RSK) (11) ROCK (2) TGF-beta/Smad (1) VEGFR (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (3) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (13)

AMPK (2)

Apoptosis (5)

Autophagy (4)

EGFR (3)

Endogenous Metabolite (1)

ERK (1)

FAK (1)

Glucosidase (1)

Glucosylceramide Synthase (GCS) (1)

HIF/HIF Prolyl-Hydroxylase (1)

HSP (1)

HSV (1)

Mitochondrial Metabolism (1)

mTOR (3)

Necroptosis (1)

NF-κB (3)

Oxidative Phosphorylation (1)

p38 MAPK (2)

PDK-1 (1)

PI3K (3)

PKA (3)

Proteasome (1)

Reactive Oxygen Species (1)

Ribosomal S6 Kinase (RSK) (11)

ROCK (2)

TGF-beta/Smad (1)

VEGFR (1)

By Research Areas:

Cancer (27)

Cardiovascular Disease (3)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152944

S6K1-IN-DG2	Ribosomal S6 Kinase (RSK)	Cancer
S6K1-IN-DG2 (Compound 66) is a *p70S6K* inhibitor (IC₅₀: < 100 nM) .

HY-100501

M2698 MSC2363318A	Ribosomal S6 Kinase (RSK) Akt	Cancer
M2698 (MSC2363318A) is an orally active, ATP competitive, selective *p70S6K* and Akt dual-inhibitor with IC₅₀s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .

HY-14362

GSK-25	ROCK Ribosomal S6 Kinase (RSK)	Cardiovascular Disease
GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC₅₀=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC₅₀=398 nM, p70S6K: IC₅₀=1 μM). GSK-25 inhibits P450 profile (IC₅₀s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively) .

HY-110313

SB-747651A dihydrochloride	p38 MAPK	Inflammation/Immunology
SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC₅₀ of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research .

HY-120035

DD1	Proteasome Ribosomal S6 Kinase (RSK) Apoptosis	Cancer
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation .

HY-13595

Chrysophanol 3 Publications Verification Chrysophanic acid	EGFR	Cancer
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-12493A

LY-2584702 tosylate salt Maximum Cited Publications 6 Publications Verification	Ribosomal S6 Kinase (RSK)	Cancer
LY-2584702 tosylate salt is a selective ATP competitive inhibitor of *p70S6K* with an IC₅₀ of 4 nM. In S6K1 enzyme assay, the IC₅₀ of LY-2584702 is 2 nM.

HY-130723

AMPK activator 2	AMPK	Cancer
AMPK activator 2 (compound 7a), a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-P0141

Akt/SKG Substrate Peptide	Akt	Others
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1 .

HY-P0141A

Akt/SKG Substrate Peptide TFA	Akt	Others
Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1 .

HY-12493B

LY-2584702 hydrochloride	Ribosomal S6 Kinase (RSK)	Cancer
LY-2584702 hydrochloride is a selective ATP competitive inhibitor of *p70S6K* with an IC₅₀ of 4 nM. In S6K1 enzyme assay, the IC₅₀ of LY-2584702 is 2 nM.

HY-12493

LY-2584702 free base	Ribosomal S6 Kinase (RSK)	Cancer
LY-2584702 free base is a selective ATP competitive inhibitor of *p70S6K* with an IC₅₀ of 4 nM. In S6K1 enzyme assay, the IC₅₀ of LY-2584702 is 2 nM.

HY-130723A

AMPK activator 2 hydrochloride	AMPK	Cancer
AMPK activator 2 (compound 7a) hydrochloride, a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 hydrochloride inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-N1333

Rubioncolin C	NF-κB	Cancer
Rubioncolin C exerts anti-tumor activity by inducing apoptotic and autophagic Cell Death and inhibiting the NF-κB and *Akt/mTOR/P70S6K* Pathway in Human Cancer Cells .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	EGFR	Cancer
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

HY-16071

AT13148 2 Publications Verification	Akt PKA ROCK Ribosomal S6 Kinase (RSK)	Cancer
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC₅₀s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.

HY-12059

AT7867 4 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and *p70S6K/PKA* with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-12059A

AT7867 dihydrochloride 4 Publications Verification	Akt PKA Ribosomal S6 Kinase (RSK)	Cancer
AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and *p70S6K/PKA* with IC₅₀s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.

HY-114038

SB-747651A	p38 MAPK	Inflammation/Immunology
SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC₅₀ of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research .

HY-N1050

Zederone	mTOR	Cancer
Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

HY-13260

CCT128930 5 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC₅₀=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). Antitumor activity.

HY-13260A

CCT128930 hydrochloride 5 Publications Verification	Akt Autophagy Apoptosis	Cancer
CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC₅₀=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC₅₀=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC₅₀=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .

HY-117885

PF-5177624	PDK-1	Cancer
PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .

HY-148877

AT-533	HSP HSV HIF/HIF Prolyl-Hydroxylase VEGFR NF-κB ERK Akt FAK	Infection Inflammation/Immunology Cancer
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including *Akt/mTOR/p70S6K, Erk1/2* and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs) .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-N8380

(-)-Latifolin	Apoptosis Autophagy PI3K Necroptosis	Cardiovascular Disease Inflammation/Immunology Cancer
(-)-Latifolin, a flavonoid, induces apoptotic cell death by targeting *PI3K/AKT/mTOR/p70S6K* signaling. (-)-Latifolin significantly inhibits the cell proliferation of oral squamous cell carcinoma (OSCC), and causes the anti-metastatic activities by effectively blocking cell migration, invasion, and adhesion via the inactivation of FAK/Src. (-)-Latifolin suppresses autophagic-related proteins and autophagosome formation. (-)-Latifolin inhibits necroptosis by dephosphorylating necroptosis-regulatory proteins (RIP1, RIP3, and MLKL). (-)-Latifolin has beneficial effects on anti-aging, anti-carcinogenic, anti-inflammatory, and cardio-protective activities .

HY-N0847

Micheliolide 4 Publications Verification	NF-κB PI3K Akt TGF-beta/Smad	Inflammation/Immunology Cancer
Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .

HY-155721

22-(4′-py)-JA 22-(4′-Pyridinecarbonyl) jorunnamycin A	Akt mTOR	Cancer
22-(4′-py)-JA is a semisynthetic derivative of junamycin A (JA) that can be isolated from the Thai blue sponge (Xestospongia sp.). 22-(4′-py)-JA has antimetastatic activity and can inhibit AKT/mTOR/p70S6K signaling. 22-(4′-py)-JA inhibits tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC), downregulates metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). 22-(4′-py)-JA has potent anticancer activity against non-small cell lung cancer (NSCLC) .

HY-18313

S6K1-IN-1	Ribosomal S6 Kinase (RSK)	Metabolic Disease
S6K-18 is a potent and selective *p70S6K1* inhibitor with an IC₅₀ of 52 nM .

HY-134832

Mito-LND 2 Publications Verification Mito-Lonidamine	Oxidative Phosphorylation Mitochondrial Metabolism Reactive Oxygen Species Autophagy	Cancer
Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells .

HY-112234

L-Sepiapterin Sepiapterin	Endogenous Metabolite	Cancer
L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 ^S6K-dependent VEGFR-2 expression .

HY-114615

AMP-Deoxynojirimycin AMP-DNM	Glucosidase Glucosylceramide Synthase (GCS)	Neurological Disease
AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor .

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .

Cat. No.	Product Name	Target	Research Area

HY-P0141

Akt/SKG Substrate Peptide	Akt	Others
Akt/SKG Substrate Peptide is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1 .

HY-P0141A

Akt/SKG Substrate Peptide TFA	Akt	Others
Akt/SKG Substrate Peptide TFA is a synthetic peptide suitable as a substrate for Akt/PKB, which is not phosphorylated by p70S6K or MAPK1 .

HY-P10042

S6K Substrate	Peptides	Others
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 .

HY-P10320

T3 Peptide Tumstatin (69-88), human	PI3K Akt	Cardiovascular Disease
T3 Peptide is an active fragment of tumstatin. T3 Peptide binds integrin α_vβ₃/α_vβ₅, activates the PI3K/Akt/p70S6K signaling pathway, and thus stimulates the proliferation and migration of rat cardiac fibroblasts .

Cat. No.	Product Name	Target	Research Area

HY-P99507

Zenocutuzumab MCLA-128; PB4188; R040517	EGFR	Cancer
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .

Chrysophanol 3 Publications Verification Chrysophanic acid	Quinones Structural Classification Rheum palmatum L. Classification of Application Fields Anthraquinones Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and *mTOR/p70S6K*.

Zederone	Structural Classification Terpenoids Sesquiterpenes Source classification Plants Curcuma elata Roxb. Zingiberaceae	mTOR
Zederone, a germacrane-type sesquiterpene, has potently cytotoxic against human white blood cancer cells and human prostate cancer cells. Zederone significantly inhibits the proliferation and downregulates the protein expressions of mTOR, and phosphorylated p70 S6 kinase (p-p70s6K) in SKOV3 cells .

Micheliolide 4 Publications Verification	Structural Classification Other Monoterpenes other families Classification of Application Fields Terpenoids Source classification Other Diseases Plants Disease Research Fields	NF-κB PI3K Akt TGF-beta/Smad
Micheliolide is a sesquiterpene lactone with anti-cancer and anti-inflammatory effects, which is derived from Michelia compressa and Michelia champaca. Micheliolide can attenuate high glucose-stimulated NF-κB activation, IκBα degradation, and the expression of MCP-1, TGF-β1, and FN in mouse mesangial cells. Micheliolide inhibits LPS (HY-D1056)-induced activation of NF-κB and PI3K/Akt/p70S6K pathways to play an anti-inflammatory role. Micheliolide inhibits dextran sodium sulphate (DSS) (HY-116282)-induced inflammatory intestinal disease, colitis-associated cancer and rheumatic arthritis .

Cat. No.	Compare	Product Name	Species	Source

HY-P76588

	S6K1/RPS6KB1 Protein, Human (sf9, GST) Ribosomal protein S6 kinase beta-1; S6K1; p70S6K1; p70 S6KA; RPS6KB1; STK14A	Human	Sf9 insect cells
	S6K1/RPS6KB1 is a kinase downstream of mTOR that regulates cellular processes critical for proliferation, growth, and cell cycle. It phosphorylates EIF4B, RPS6 and EEF2K and regulates protein synthesis by inhibiting the pro-apoptotic function of BAD, thereby enhancing cell survival. S6K1/RPS6KB1 Protein, Human (sf9, GST) is the recombinant human-derived S6K1/RPS6KB1 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82145

	Phospho-S6K2 (Ser371) Antibody (YA1890) RPS6KB2; STK14B; Ribosomal protein S6 kinase beta-2; S6K-beta-2; S6K2; 70 kDa ribosomal protein S6 kinase 2; p70S6K2; p70-S6K 2; S6 kinase-related kinase; SRK; Serine/threonine-protein kinase 14B; p70 ribosomal S6 kinase beta; S6K-beta; p70	WB	Human, Mouse, Rat
	Phospho-S6K2 (Ser371) Antibody (YA1890) is a biotin-conjugated non-conjugated IgG antibody, targeting Phospho-S6K2 (Ser371), with a predicted molecular weight of 53 kDa (observed band size: 60 kDa). Phospho-S6K2 (Ser371) Antibody (YA1890) can be used for WB experiment in human, mouse, rat background.

HY-P81209

	S6K1 Antibody 70 kDa ribosomal protein S6 kinase 1 antibody; KS6B1_HUMAN antibody; p70 alpha antibody; P70 beta 1 antibody p70 ribosomal S6 kinase alpha antibody; p70 ribosomal S6 kinase beta 1 antibody; p70 S6 kinase alpha antibody; P70 S6 Kinase antibody; p70 S6 kinase, alpha 1 antibody; p70 S6 kinase, alpha 2 antibody; p70 S6K antibody; p70 S6K-alpha antibody; p70 S6KA antibody; p70(S6K) alpha antibody; p70(S6K)-alpha antibody; p70-alpha antibody; p70-S6K 1 antibody; p70-S6K antibody; p70S6K antibody; p70S6K1 antibody; p70S6Kb antibody; PS6K antibody; Ribosomal protein S6 kinase 70kDa polypeptide 1 antibody; Ribosomal protein S6 kinase beta 1 antibody; Ribosomal protein S6 kinase beta-1 antibody; Ribosomal protein S6 kinase I antibody; RPS6KB1 antibody; S6K antibody; S6K-beta-1 antibody; S6K1 antibody; Serine/threonine kinase 14 alpha antibody; Serine/threonine-protein kinase 14A antibody; STK14A antibody	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Rat
	S6K1 Antibody is an unconjugated, approximately 59 kDa, rabbit-derived, anti-S6K1 monoclonal antibody. S6K1 Antibody can be used for: WB, ICC/IF, IP expriments in human, rat, mouse background without labeling.

HY-P81769

	S6K2 Antibody (YA1514) RPS6KB2; STK14B; Ribosomal protein S6 kinase beta-2; S6K-beta-2; S6K2; 70 kDa ribosomal protein S6 kinase 2; p70S6K2; p70-S6K 2; S6 kinase-related kinase; SRK; Serine/threonine-protein kinase 14B; p70 ribosomal S6 kinase beta; S6K-beta; p70	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	S6K2 Antibody (YA1514) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1514), targeting S6K2, with a predicted molecular weight of 53 kDa (observed band size: 53 kDa). S6K2 Antibody (YA1514) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human, mouse, rat background.